NASDAQ: QTRXQuanterix Corp Stock
$5.15-0.01 (-0.19%)
Updated Apr 17, 2025
QTRX Price
$5.15
Fair Value Price
N/A
Market Cap
$199.70M
52 Week Low
$4.67
52 Week High
$19.18
P/E
-5.15x
P/B
0.61x
P/S
2.97x
PEG
N/A
Dividend Yield
N/A
Revenue
$137.42M
Earnings
-$38.53M
Gross Margin
60.5%
Operating Margin
-27.72%
Profit Margin
-28%
Debt to Equity
0.23
Operating Cash Flow
-$35M
Beta
1.76
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
QTRX Overview
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine QTRX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
QTRX
Ranked#72 of 102
Ranked#72 of 102
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.82 | A | |
| $22.79 | A | |
| $13.33 | A |
Be the first to know about important QTRX news, forecast changes, insider trades & much more!
QTRX News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how QTRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QTRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
QTRX is good value based on its book value relative to its share price (0.61x), compared to the US Medical Devices industry average (3.8x)
P/B vs Industry Valuation
QTRX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more QTRX due diligence checks available for Premium users.
Valuation
QTRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.15x
Industry
41.14x
Market
27.98x
QTRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.61x
Industry
3.8x
QTRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
QTRX's financial health
Profit margin
Revenue
$35.2M
Net Income
-$11.6M
Profit Margin
-33.1%
QTRX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
QTRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$406.5M
Liabilities
$76.5M
Debt to equity
0.23
QTRX's short-term assets ($363.59M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QTRX's short-term assets ($363.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QTRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
QTRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.3M
Investing
$32.4M
Financing
$41.0k
QTRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
QTRX vs Medical Device Stocks
Quanterix Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.